Xin Lang Cai Jing·2026-01-22 03:34Core Viewpoint - The articles discuss ongoing investor compensation cases against companies Xilong Science and Puli Pharmaceutical due to false financial disclosures, highlighting the legal actions taken by investors and the financial discrepancies identified by regulatory authorities [1][2][4][5]. Group 1: Xilong Science - Xilong Science has faced legal actions due to false statements leading to investor compensation claims, with a recent case submitted to the Shantou Intermediate People's Court [1][4]. - The company was found to have inflated its financial figures significantly, with 2020 showing inflated revenue of approximately 597.65 million yuan, costs of about 595.99 million yuan, and profits of around 1.66 million yuan, representing 9.57%, 10.34%, and 2.04% of total revenue, costs, and profits respectively [1][4]. - For 2021, the inflated revenue was approximately 1.46 billion yuan, costs around 1.44 billion yuan, and profits about 13.48 million yuan, accounting for 21.32%, 22.98%, and 5.93% of total revenue, costs, and profits respectively [1][4]. Group 2: Puli Pharmaceutical - Puli Pharmaceutical is also facing investor compensation claims, with a recent case submitted to the Haikou Intermediate People's Court, where investors have won a preliminary judgment [2][5]. - The company was found to have overstated its revenue by approximately 514.60 million yuan in 2021, which constituted 34.11% of the reported revenue, and inflated profits by about 308.02 million yuan, making up 65.88% of the total profit [2][5]. - In 2022, the company overstated its revenue by approximately 515.90 million yuan, representing 28.56% of the reported revenue, and inflated profits by about 387.42 million yuan, which was 88.27% of the total profit [2][5]. Group 3: Legal Context - Investors who purchased shares of Puli Pharmaceutical between April 26, 2022, and April 17, 2024, or shares of Xilong Science between April 29, 2021, and April 29, 2023, are eligible to initiate compensation claims [3][6]. - The legal actions are being led by attorney Xu Feng from Shanghai Jucheng Law Firm, who has extensive experience in securities fraud cases [3][6].